Access

Correspondence

Nature 440, 605 (30 March 2006) | doi:10.1038/440605d; Published online 29 March 2006

Open Innovation Challenges

naturejobs

Populations who test drugs should benefit from them

Sanjay Basu1, Jason Andrews1 & Duncan Smith-Rohrberg1

  1. Yale University School of Medicine, 129 York Street, New Haven, Connecticut 06511, USA

Paul Herrling, in his Commentary article "Experiments in social responsibility" (Nature 439, 267–268; 2006), describes pharmaceutical companies moving towards a more progressive approach to drug development and distribution in poor countries. But it is important to note that, even when research in developing nations leads to effective treatments, there is still the danger of local populations being exploited.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

RESEARCH

Structure of the Mad2 spindle assembly checkpoint protein and its interaction with Cdc20

Nature Structural Biology Article (01 Mar 2000)

Molecular mechanism of NPF recognition by EH domains

Nature Structural Biology Letter (01 Nov 2000)